<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Sabbatini, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don S Dizon, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1846264236">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epithelial cancers of ovarian, fallopian tube, and peritoneal origin exhibit similar clinical characteristics, behavior, and in many cases, share basic biology. As such, these are often considered collectively and define epithelial ovarian cancer (EOC) in clinical trials and clinical practice. This topic will consider all three primary sites under the heading EOC.
        </p>
        <p>
         Despite initial therapy (usually consisting of surgical cytoreduction and platinum-taxane combination therapy), the majority of women with advanced-stage ovarian cancer will relapse and require additional treatment. The likelihood for recurrence depends on many factors, including distribution of disease at initial presentation, success of initial surgical cytoreduction (ie, the presence of any residual disease), rapidity of cancer antigen (CA) 125 resolution, and treatment response after primary therapy. However, a predictive marker for recurrence has not been prospectively verified.
        </p>
        <p>
         The management of patients with platinum-sensitive recurrent ovarian cancer (ie, those with a platinum-free interval of six months or longer) is discussed here. (See
         <a class="local">
          'Relevance of the platinum-free interval'
         </a>
         below.)
        </p>
        <p>
         The management of patients with platinum-resistant disease (those with a platinum-free interval of less than six months), as well as the initial diagnosis and management of EOC, and the surgical treatment of recurrent EOC are covered separately. (See
         <a class="medical medical_review" href="/z/d/html/3240.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-resistant disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83397.html" rel="external">
          "Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3196.html" rel="external">
          "Cancer of the ovary, fallopian tube, and peritoneum: Surgical options for recurrent cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3239.html" rel="external">
          "First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3238.html" rel="external">
          "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1138765547">
         <span class="h1">
          RELEVANCE OF THE PLATINUM-FREE INTERVAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of relapsed disease is frequently stratified based upon the amount of time that has elapsed between the completion of platinum-based treatment and the detection of relapse, known as the platinum-free interval (PFI). This is because the PFI correlates with progression-free survival (PFS), overall survival (OS), and response to subsequent treatment (both with platinum and nonplatinum agents as well as cytoreduction):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with a PFI of six months or longer are considered to have chemotherapy-sensitive disease (often also termed "platinum-sensitive").
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with a PFI of less than six months are considered to have chemotherapy-resistant disease (often also termed "platinum-resistant"). Of this group, those patients who progress while on platinum-based therapy are often referred to as having "platinum-refractory" disease. The management of these patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3240.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-resistant disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Although a longer PFI has been associated with better outcomes, the strategy of artificially extending the PFI with a nonplatinum regimen does not appear to improve survival outcomes compared with the use of platinum. In the MITO8 trial, 215 patients with progression 6 to 12 months after platinum-based chemotherapy were randomly assigned to nonplatinum-based chemotherapy followed at progression by platinum-based chemotherapy, or the reverse treatment sequence [
         <a href="#rid1">
          1
         </a>
         ]. The nonplatinum-based therapy consisted of
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">
          topotecan
         </a>
         , or
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , and the platinum-based therapy was
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         with either
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         or gemcitabine. Although median PFS was increased (9.0 versus 5.0 months), the median OS was not improved with initial nonplatinum-based chemotherapy (21.8 versus 24.5 months; hazard ratio [HR] for death 1.38, 95% CI 0.99-1.94). It should be noted, however, that this study was terminated before meeting its primary accrual target.
        </p>
        <p class="headingAnchor" id="H1846264320">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with platinum-sensitive recurrent EOC should be considered for both secondary cytoreduction and second-line chemotherapy, with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         . The use of second-line chemotherapy is discussed in the following sections. Secondary cytoreduction is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3196.html" rel="external">
          "Cancer of the ovary, fallopian tube, and peritoneum: Surgical options for recurrent cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4501538">
         <span class="h2">
          Selection of regimen
         </span>
        </p>
        <p class="headingAnchor" id="H3152385663">
         <span class="h3">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who relapse six months or longer after receiving initial therapy with a platinum-based treatment are more likely to respond to retreatment with a chemotherapy regimen that contains a platinum agent (eg,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ). In general, combination chemotherapy is preferred to single-agent chemotherapy because in most cases, it is associated with superior objective response and progression-free survival (PFS) [
         <a href="#rid2">
          2-10
         </a>
         ].
        </p>
        <p>
         In addition, several trials suggest that women with platinum-sensitive disease achieve better response rates and PFS using maintenance treatment. However, single-agent therapy may be appropriate for medically frail patients or those with lingering toxicities from prior therapy.
        </p>
        <p>
         While the ideal platinum-based combination therapy is not known, options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          Carboplatin
         </a>
         (area under the curve [AUC] 5) plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         (175 mg/m
         <sup>
          2
         </sup>
         ) IV  (
         <a class="graphic graphic_table graphicRef65626" href="/z/d/graphic/65626.html" rel="external">
          table 1
         </a>
         ), with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         (15 mg/kg), every three weeks [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          Carboplatin
         </a>
         (AUC 4) plus
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         (1000 mg/m
         <sup>
          2
         </sup>
         on days 1 and 8) IV, with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , every three weeks [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is used for either of the above regimens, it should be continued without chemotherapy as maintenance treatment. (See
         <a class="local">
          'Bevacizumab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          Carboplatin
         </a>
         (AUC 5) and
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         (PLD, 30 mg/m
         <sup>
          2
         </sup>
         ) IV with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         (10 mg/kg biweekly) every four weeks [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         While
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         is the only agent that has shown an OS benefit when combined with platinum-based chemotherapy in a clinical trial, these data are limited. (See
         <a class="local">
          'Combination therapy'
         </a>
         below.)
        </p>
        <p>
         Ultimately, decisions should be individualized based on clinician and patient preferences, considering the side effect profile of each agent.
        </p>
        <p>
         For example, for women with residual neuropathy or those who express a strong preference not to lose their hair,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         or PLD may be the preferred partner with
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         , rather than
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         . For women who travel from a far distance, PLD may be the preferred option since it is administered on an every-four-week schedule in combination with carboplatin. Another consideration is that if
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is planned in the platinum-sensitive setting, current approvals allow combinations with carboplatin and either gemcitabine or paclitaxel only (not PLD). (See
         <a class="medical medical_review" href="/z/d/html/90087.html" rel="external">
          "The approach to ovarian cancer in older women", section on 'Treatment of recurrent disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/142102.html" rel="external">
          "Toxic erythema of chemotherapy (hand-foot syndrome)", section on 'Hand-foot syndrome'
         </a>
         .)
        </p>
        <p>
         In addition to the regimens listed above, several other choices are used in clinical practice such as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The substitution of
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         for
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of weekly
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         in combination with platinum [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The combination of
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         (800 to 1000 mg/m
         <sup>
          2
         </sup>
         ) plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (30 to 40 mg/m
         <sup>
          2
         </sup>
         ) – Although this has been administered predominately in patients with platinum-resistant disease [
         <a href="#rid17">
          17
         </a>
         ], in our experience, it is an effective alternative to
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         plus gemcitabine when patients experience repeat delays due to myelosuppression (although myelosuppression may also be mitigated by dose reduction of gemcitabine).
        </p>
        <p>
        </p>
        <p>
         Both high-dose chemotherapy with autologous hematopoietic cell transplantation and the use of intraperitoneal chemotherapy have been evaluated in women with recurrent EOC. However, there is no evidence that either of these approaches improves survival outcomes compared with standard IV chemotherapy. These approaches are investigational and should not be considered standard of care options.
        </p>
        <p class="headingAnchor" id="H1846264327">
         <span class="h3">
          Combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combination chemotherapy in the treatment of women with platinum-sensitive EOC was evaluated in multiple phase III studies. In general, platinum-based combination therapy demonstrates consistent improvements in response and PFS with overall response rates (complete plus partial response rates, [ORR]) from 50 to 60 percent, with additional benefit from the addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         . Multiple combinations are acceptable; however, the ideal platinum-based combination is not known.
        </p>
        <p>
         Selection of regimen, as well as rationale for inclusion of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , is discussed separately. (See
         <a class="local">
          'General principles'
         </a>
         above and
         <a class="local">
          'Bevacizumab'
         </a>
         below.)
        </p>
        <p>
         Supporting data describing each regimen are discussed here.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carboplatin
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          paclitaxel
         </strong>
         – In parallel phase III trials conducted by the International Collaboration on Ovarian Neoplasms (ICON-4) and the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR-2.2), 802 women were treated with conventional platinum-based chemotherapy (eg,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         alone; or
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [CAP]) with or without
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         [
         <a href="#rid11">
          11
         </a>
         ]. With a median follow-up of 42 months, those receiving platinum-based chemotherapy with paclitaxel experienced improved survival (29 versus 24 months; hazard ratio [HR] 0.82, 95% CI 0.69-0.97). There was also a higher incidence of grade 2 to 4 neurologic effects (20 versus 1 percent) and alopecia (86 versus 25 percent) for those receiving paclitaxel, though rates of myelosuppression were lower.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This is only one of two studies to date that has documented an improvement in OS; however, it has been criticized due to the high proportion of taxane-naïve patients entering into the trial (nearly 30 percent of patients in the control arm were never treated with a taxane as part of initial or subsequent therapy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carboplatin
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          gemcitabine
         </strong>
         – A phase III study conducted by the Gynecologic Cancer Intergroup (GCIG) enrolled 356 women and randomly assigned therapy with 21-day cycles of
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         alone or carboplatin plus
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ]. Compared with single-agent carboplatin, combined therapy resulted in an improved objective response rate (47 versus 31 percent) and median PFS (8.6 versus 5.8 months), although OS was not improved (18 versus 17.3 months, respectively). Patients receiving gemcitabine experienced an increase in serious (grade 3/4) hematologic toxicity, including neutropenia (71 versus 12 percent) and thrombocytopenia (35 versus 11 percent), and required granulocyte colony stimulating factors (G-CSF) more frequently (24 versus 10 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carboplatin
         </strong>
         <strong>
          plus PLD
         </strong>
         – The combination of
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and PLD is an effective combination for platinum-sensitive EOC [
         <a href="#rid18">
          18-21
         </a>
         ]. The efficacy of this combination was best shown in the phase III Caelyx in platinum-sensitive EOC (CALYPSO) trial, which was the largest phase III trial in the recurrent setting to be completed [
         <a href="#rid18">
          18,19
         </a>
         ]. This study enrolled 976 women and randomly assigned them to treatment with carboplatin and either
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         or PLD. With a median follow-up of 22 months, compared with carboplatin plus paclitaxel, PLD plus carboplatin resulted in improvement in median PFS (11.3 versus 9.4 months), although OS was equivalent (30.7 with carboplatin plus PLD versus 33.0 months with carboplatin plus paclitaxel [HR 0.99, 95% CI 0.85-1.16]) [
         <a href="#rid19">
          19,20
         </a>
         ]. There were also fewer cases of severe (grade 3/4) neutropenia (35 versus 46 percent), lesser-grade neuropathy (5 versus 27 percent), and carboplatin hypersensitivity reactions (16 versus 33 percent). However, there were more cases of severe (grade 3/4) thrombocytopenia (16 versus 6 percent) among those receiving PLD.
        </p>
        <p>
        </p>
        <p>
         Taken together, these data support the superiority of a platinum-based combination compared with single-agent platinum for initial treatment of relapsed disease. When platinum cannot be given to patients with platinum-sensitive disease (due to previous hypersensitivity or other comorbidities), single nonplatinum agents are often used. (See
         <a class="local">
          'Single-agent therapy'
         </a>
         below.)
        </p>
        <p>
         Several studies have proposed doublets of nonplatinum agents, but no clear consensus exists as to whether they are superior to single agents in this setting [
         <a href="#rid22">
          22-24
         </a>
         ]. As an example, PLD has been combined with
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         , a novel marine-derived alkaloid that kills cells by poisoning the DNA nucleotide excision repair machinery. In the OVA-301 study, approximately 700 women were randomly assigned to treatment with PLD (50 mg/m
         <sup>
          2
         </sup>
         every four weeks) or PLD (30 mg/m
         <sup>
          2
         </sup>
         ) plus trabectedin (1.1 mg/m
         <sup>
          2
         </sup>
         over three hours) [
         <a href="#rid25">
          25
         </a>
         ]. Compared with single-agent PLD, the combination of trabectedin plus PLD resulted in improved PFS for those with platinum-sensitive disease (median, 9.2 versus 7.5 months; HR 0.73, 95% CI 0.56-0.95), but not those with platinum-resistant disease (4 months in both arms) [
         <a href="#rid23">
          23,26
         </a>
         ]. Median OS was equivalent between arms in both the platinum-sensitive and platinum-resistant cohorts. Overall, treatment was well-tolerated; neutropenia and grade 3 or 4 transaminase elevation were more common in the trabectedin group, while hand-foot syndrome and mucositis were less common. Based on these results, trabectedin is approved for use in ovarian cancer in Europe and other countries, but not in the United States (US).
        </p>
        <p class="headingAnchor" id="H1224704057">
         <span class="h3">
          Single-agent therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platinum-based combination chemotherapy is the preferred treatment for most patients with platinum-sensitive relapsed EOC. A subset of women may not be candidates for retreatment with platinum agents (eg,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) either due to a history of a hypersensitivity reaction or persistent toxicities from first-line therapy. Such patients may be candidates for single-agent therapy with other drugs. The following agents are among the most active agents for women with platinum-sensitive recurrent EOC. A choice among them should take into account patient preferences and toxicity profile:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etoposide
         </strong>
         – A Gynecologic Oncology Group (GOG) study involved 82 patients who were treated with
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (50 mg/m
         <sup>
          2
         </sup>
         given orally for 21 days of a 28-day cycle). Among the group with platinum-sensitive EOC (n = 41), the ORR was 34 percent [
         <a href="#rid27">
          27
         </a>
         ]. Serious toxicities (grade 3/4) are predominantly hematologic (neutropenia, thrombocytopenia, and leukopenia). There is also a 2 percent risk of secondary leukemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topotecan
         </strong>
         – In a phase III study that included 474 women with recurrent EOC, all patients were randomly assigned to PLD or
         <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">
          topotecan
         </a>
         (1.5 mg/m
         <sup>
          2
         </sup>
         /day for five days every 21 days) [
         <a href="#rid28">
          28
         </a>
         ]. Among platinum-sensitive patients treated with topotecan, the ORR was 29 percent. An alternative weekly schedule (4 mg/m
         <sup>
          2
         </sup>
         weekly) was evaluated in a cohort of 43 patients and resulted in a 24 percent ORR [
         <a href="#rid29">
          29
         </a>
         ]. Serious toxicity is predominantly hematologic. Several studies have suggested lower starting doses (ie, 1 to 1.25 mg/m
         <sup>
          2
         </sup>
         for five days every 21 days) to ameliorate hematologic toxicity [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pegylated liposomal doxorubicin
         </strong>
         – In the randomized trial of PLD versus
         <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">
          topotecan
         </a>
         discussed above, PLD (50 mg/m
         <sup>
          2
         </sup>
         every 28 days) resulted in an ORR of 28 percent among platinum-sensitive patients [
         <a href="#rid28">
          28
         </a>
         ]. It should be noted that while the US Food and Drug Administration (FDA)-approved dose is 50 mg/m
         <sup>
          2
         </sup>
         , most clinicians start at a lower dose (40 mg/m
         <sup>
          2
         </sup>
         ) to reduce the risk of skin toxicity
         <sup>
         </sup>
         while maintaining the activity of this agent (versus 30 mg/m
         <sup>
          2
         </sup>
         when given in combination with
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gemcitabine
         </strong>
         – In a phase III trial that included 153 patients randomly assigned treatment with PLD or
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         (1000 mg/m
         <sup>
          2
         </sup>
         on days 1, 8, and 15 of a 28-day cycle) [
         <a href="#rid32">
          32
         </a>
         ], treatment with gemcitabine resulted in an ORR of 29 percent. Neutropenia is a common toxicity of this agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nanoparticle albumin-bound
         </strong>
         <strong>
          paclitaxel
         </strong>
         <strong>
          (
         </strong>
         <strong>
          nabpaclitaxel
         </strong>
         <strong>
          )
         </strong>
         –
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          Nabpaclitaxel
         </a>
         (260 mg/m
         <sup>
          2
         </sup>
         on day 1 every three weeks or 100 mg/m
         <sup>
          2
         </sup>
         on days 1, 8, and 15 on a 28-day schedule) was evaluated in a cohort of 47 women with recurrent EOC and resulted in an ORR of 64 percent [
         <a href="#rid33">
          33
         </a>
         ]. Nabpaclitaxel may also be given weekly (80 to 100 mg/m
         <sup>
          2
         </sup>
         on days 1, 8, and 15 on a 28-day schedule), as has been studied in the platinum-resistant setting [
         <a href="#rid34">
          34
         </a>
         ]. The most common toxicities are neutropenia and neuropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trabectedin
         </strong>
         – Although it is not available in the US,
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         is approved in both Europe and Canada for treatment of relapsed EOC. Trabectedin has activity in women previously treated with platinum and taxanes, but has shown most of its activity in women who relapse with platinum-sensitive disease, as demonstrated in two phase II trials:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a multi-institutional European study, 59 women received
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         (1300 mcg/m
         <sup>
          2
         </sup>
         over three hours every three weeks) [
         <a href="#rid35">
          35
         </a>
         ]. Among 29 women with platinum-sensitive disease, the ORR was 43 percent; in the 30 women with platinum-resistant disease, only two responses were recorded (7 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a separate study, 141 women (62 platinum-sensitive, 79 platinum-resistant) were treated with
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         on a four-week cycle (580 mcg/m
         <sup>
          2
         </sup>
         over three hours weekly for three weeks followed by one week off) [
         <a href="#rid36">
          36
         </a>
         ]. Among women with platinum-sensitive disease, the ORR was 29 percent with a median PFS of five months. Among those with platinum-resistant disease, the ORR was 6 percent with a median PFS of two months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bevacizumab
         </strong>
         – As mentioned previously, this agent is frequently administered in the context of chemotherapy; however, several phase II trials evaluating its activity as a single agent have included patients with platinum-sensitive disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the GOG trial 170-D, 11 responses (44 percent) were seen among 25 patients (41 percent of the total population) with potentially platinum-sensitive recurrent disease, including two complete responses [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In another phase II trial in which
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         was given in combination with metronomically administered
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , 42 patients (60 percent of the total population) had potentially platinum-sensitive disease, among whom 14 (33 percent) had an objective partial response. The median time to progression (TTP) was approximately eight months and was significantly longer than the platinum-resistant subgroup [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H511569130">
         <span class="h2">
          Maintenance therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3549931479">
         <span class="h3">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our typical approach for women with platinum-sensitive recurrent EOC that is not breast cancer susceptibility gene (
         <em>
          BRCA
         </em>
         ) associated is to treat with the combination of
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and either
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         or
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , followed by bevacizumab alone as maintenance therapy.
        </p>
        <p>
         The approach to maintenance therapy among patients with
         <em>
          BRCA
         </em>
         -associated ovarian cancers is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/121057.html" rel="external">
          "Management of ovarian cancer associated with BRCA and other genetic mutations", section on 'Choosing between a PARP inhibitor and an angiogenesis inhibitor'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2279516761">
         <span class="h3">
          Angiogenesis inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angiogenesis plays a fundamental role in normal ovarian physiology and in the pathogenesis of EOC, progression through ascites formation, and metastatic spread. Angiogenesis inhibitors appear to be active agents in the treatment of EOC. Among them, the agent that has been most extensively evaluated in the treatment of platinum-sensitive EOC is
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         .
        </p>
        <p>
         While PFS has been the subject of most clinical trials, only GOG-213, evaluating
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , was powered to address OS.
        </p>
        <p class="headingAnchor" id="H2289542103">
         <span class="h4">
          Bevacizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest the use of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         with combination platinum-based chemotherapy and then as single-agent maintenance treatment for women with platinum-sensitive recurrent EOC. The data regarding bevacizumab specifically for women with platinum-sensitive recurrent EOC come from several randomized trials [
         <a href="#rid14">
          14,39-43
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          OCEANS trial
         </strong>
         – In the phase III study of
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         in EOC (also referred to as the OCEANS study), 484 women with platinum-sensitive EOC were randomly assigned to carboplatin (AUC 4 on day 1) and gemcitabine (1000 mg/m
         <sup>
          2
         </sup>
         on days 1 and 8) with cycles repeated every 21 days with or without bevacizumab (15 mg/kg on day 1 every three weeks concurrent with chemotherapy for 10 cycles maximum, followed by bevacizumab alone until disease progression or toxicity) [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         with chemotherapy resulted in the following when compared with chemotherapy plus placebo:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An improvement in PFS (12 versus 8 months; HR 0.48, 95% CI 0.39-0.61). However, OS was not different between the two arms (34 versus 33 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A higher objective response rate (79 versus 57 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A higher rate of treatment discontinuation for adverse events (23 versus 5 percent), including higher rates of serious hypertension (17 versus &lt;1 percent), proteinuria &gt;grade 3 (9 versus 1 percent), and noncentral nervous system bleeding (6 versus 1 percent). Of note, there were no cases of gastrointestinal perforation reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GOG 213
         </strong>
         – In the GOG 213 trial, women with platinum-sensitive recurrent EOC were randomly assigned to surgical treatment (secondary cytoreduction versus no secondary cytoreduction) and separately, to chemotherapy (
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ) with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         . For those patients treated with bevacizumab, it was administered with chemotherapy and then continued as a single agent until disease progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Compared with treatment with chemotherapy alone, the administration of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         resulted in [
         <a href="#rid42">
          42
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An improvement in PFS (14 versus 10 months, respectively; HR 0.61, 95% CI 0.52-0.72).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A trend towards improved OS, which was significant upon reanalysis using corrected data obtained from electronic case report forms (43 versus 37 months, respectively; HR 0.82, 95% CI 0.68-0.996) [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Higher rates of serious (grade 3/4) gastrointestinal complications, such as perforation, necrosis, or fistula (6 versus 3 percent), and infections (13 versus 6 percent). In addition, combination treatment resulted in more reports of joint pain (15 versus 5 percent) and proteinuria (8 versus 0 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MITO-16B
         </strong>
         – For patients with recurrent, platinum-sensitive ovarian cancer and prior treatment with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , rechallenge with bevacizumab prolongs PFS, but not OS.
        </p>
        <p>
        </p>
        <p>
         Although the trials above supported using
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         in patients with recurrent platinum-sensitive ovarian cancer receiving platinum-based chemotherapy, they excluded or included only a limited number of patients who had received bevacizumab as a component of first-line treatment. In MITO-16B, among 406 patients with stage IIIB to IV recurrent ovarian cancer relapsing at least six months after last dose of platinum, who had received bevacizumab during first-line treatment, those assigned to six cycles of a platinum-based doublet with concomitant and maintenance bevacizumab had improved PFS relative to those receiving the same chemotherapy without bevacizumab (11.8 versus 8.8 months, respectively; HR 0.51, 95% CI 0.41-0.65) [
         <a href="#rid45">
          45
         </a>
         ]. OS results were similar (27 months in both groups).
        </p>
        <p>
         The data consistently demonstrate that incorporating
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         can improve PFS for women with a platinum-sensitive recurrent EOC and may also improve OS. Clinicians should discuss the potential benefits to those with platinum-sensitive disease in the context of patient preferences. For example, women with severe hypertension may opt against the use of bevacizumab.
        </p>
        <p>
         The addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         may also play a more important role for those with platinum-resistant relapsed EOC. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3240.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-resistant disease", section on 'Addition of bevacizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2202206565">
         <span class="h3">
          PARP inhibitors no longer used
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although poly(ADP-ribose) polymerase (PARP) inhibitors were previously used as maintenance therapy after treatment of platinum-sensitive relapse, this strategy no longer has regulatory approval in the United States for patients with
         <em>
          BRCA
         </em>
         wildtype cancers [
         <a href="#rid46">
          46
         </a>
         ]. We do not use this strategy, given a lack of proven survival benefit in those with
         <em>
          BRCA
         </em>
         wildtype cancers and lack of regulatory approval [
         <a href="#rid47">
          47-58
         </a>
         ]. Use of PARP inhibitors in patients with
         <em>
          BRCA
         </em>
         -associated ovarian cancer is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/121057.html" rel="external">
          "Management of ovarian cancer associated with BRCA and other genetic mutations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H468387732">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment for recurrent EOC is not curative. However, for women who achieve a response or remission to platinum-based retreatment, the durability of the second remission is an important question.
        </p>
        <p>
         Although the data on prognosis are limited, in a study of 125 women who achieved a response to second-line platinum-based therapy, only 3 percent experienced a duration that was longer than the initial platinum-free interval (PFI) [
         <a href="#rid59">
          59
         </a>
         ]. In this series, treatment was often discontinued after six cycles in responding patients, raising the question of whether a maintenance treatment would help improve the duration of second (or later) response. (See
         <a class="local">
          'Maintenance therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H468386265">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1167129282">
         <span class="h2">
          PARP inhibition in BRCA carriers
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of ovarian cancer in breast cancer susceptibility gene (
         <em>
          BRCA
         </em>
         )-associated ovarian cancer is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/121057.html" rel="external">
          "Management of ovarian cancer associated with BRCA and other genetic mutations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23567221">
         <span class="h2">
          Recurrence based on CA 125 only
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with ovarian cancer may be followed serially with the serum tumor marker cancer antigen (CA) 125. In some cases, patients with an elevated CA 125 may be defined as having disease progression (sometimes referred to as serologic progression), even in the absence of clinical symptoms or radiologic findings. For such patients, we offer surveillance rather than chemotherapy, given results of one randomized trial that showed no benefit in OS with early versus delayed treatment (ie, treatment initiated based on objective evidence of disease progression). This trial is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/17007.html" rel="external">
          "Approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinoma", section on 'Role of CA 125 surveillance'
         </a>
         .)
        </p>
        <p>
         For those with relapse by CA 125 only who prefer systemic treatment over surveillance, we suggest the administration of endocrine therapy because it appears to have some activity and is less toxic than chemotherapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The activity of
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         was demonstrated in the GOG 198 trial, which enrolled 139 patients and randomly assigned them to treatment with tamoxifen (20 mg twice daily) or
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         (100 mg daily with weekly dose escalation to a maximum dose of 400 mg daily). Tamoxifen resulted in a median progression-free survival (PFS) of three months and a median overall survival (OS) of 33 months [
         <a href="#rid60">
          60
         </a>
         ]. Of note, thalidomide resulted in a 4.5- and 24-month median PFS and OS, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a separate study of patients with estrogen receptor-positive ovarian cancer, 11 of 42 patients (26 percent) treated with
         <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">
          letrozole
         </a>
         (2.5 mg daily) had a PFS of six months or longer [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1857306159">
         <span class="h2">
          Retreatment with carboplatin and risk of hypersensitivity reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women receiving
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (as a single agent or in combination) as a second- or greater-line treatment are at risk for a hypersensitivity reaction. However, this does not necessarily exclude them as candidates for retreatment. Several protocols for carboplatin desensitization are available to help guide the treatment of women at risk for or who have had a platinum allergic reaction [
         <a href="#rid62">
          62-64
         </a>
         ]. This topic is covered in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">
          "Infusion reactions to systemic chemotherapy", section on 'Platinum drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1550028862">
         <span class="h1">
          INVESTIGATIVE APPROACHES
         </span>
        </p>
        <p class="headingAnchor" id="H500469737">
         <span class="h2">
          Combined molecular therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although it remains investigational, one trial suggests that there may be a benefit to combination molecularly targeted therapy for women with platinum-sensitive EOC, particularly for those patients lacking a known breast cancer susceptibility gene (
         <em>
          BRCA
         </em>
         ) mutation.
        </p>
        <p>
         This was shown in a randomized, phase 2 trial that included 90 women with platinum-sensitive recurrent EOC who were randomly assigned to
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         with or without cediranib [
         <a href="#rid65">
          65
         </a>
         ]. With a median follow-up of 17 months, the addition of cediranib improved progression-free survival (PFS, 17 versus 9 months, respectively; hazard ratio [HR] 0.42, 95% CI 0.23-0.76), although there were also greater frequencies of serious (grade 3/4) toxicity, including fatigue, diarrhea, and hypertension.
        </p>
        <p>
         A post-hoc analysis of this trial, which stratified patients by whether or not they carried a
         <em>
          BRCA
         </em>
         mutation (n = 47; including if it was not known, n = 43), suggested that the combination was associated with better outcomes in women who were not known to have a
         <em>
          BRCA
         </em>
         mutation. Compared with
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         alone, the median PFS was prolonged in such women with combination treatment (17 versus 6 months; HR 0.32, 95% CI 0.14-0.74). By contrast, there was no difference in PFS in those with a
         <em>
          BRCA
         </em>
         mutation (median PFS, 19 versus 17 months; HR 0.55, 95% CI 0.24-1.27). Based on these results, a confirmatory phase III trial is being planned.
        </p>
        <p class="headingAnchor" id="H3109676941">
         <span class="h2">
          Genome-wide tumor analysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individualized molecular tumor profiling holds the promise of enabling personalized selection of molecularly targeted treatment based on the specific genotype identified. Several platforms are available, including the Foundation One, Caris Target Now, and SNaPshot technology [
         <a href="#rid66">
          66,67
         </a>
         ]. However, these assays require further evaluation to determine the appropriate use of genome-wide analysis in routine clinical practice.
        </p>
        <p class="headingAnchor" id="H1169297854">
         <span class="h2">
          In-vitro chemosensitivity and resistance assays
         </span>
         <span class="headingEndMark">
          —
         </span>
         In-vitro assays of chemosensitivity or resistance have been developed as a method to select the optimal chemotherapy regimen (sensitivity assays) or identify those agents least likely to be effective (resistance assays) [
         <a href="#rid68">
          68,69
         </a>
         ]. In our view, utility and cost benefits of in-vitro chemosensitivity and chemoresistance assays have not been clearly demonstrated, and prospective validation is required prior to routine clinical adoption. However, others disagree and use these assays to help in the selection of chemotherapy in patients with relapsed EOC. The role of these assays in EOC is covered separately. (See
         <a class="medical medical_review" href="/z/d/html/3239.html" rel="external">
          "First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer", section on 'In vitro chemosensitivity and resistance assays'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16216188">
         <span class="h2">
          Heated intraperitoneal chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The administration of heated intraperitoneal chemotherapy (HIPEC) is indicated for mucinous carcinomas such as appendiceal carcinoma and pseudomyxoma peritonei. Given the tendency of recurrent ovarian cancer to present as abdominal disease, there is growing interest in the use of HIPEC for women with recurrent EOC following surgical cytoreduction. However, we consider HIPEC an investigational modality for the treatment of patients with platinum-sensitive recurrent EOC.
        </p>
        <p>
         The largest series evaluating HIPEC for recurrent EOC involved 246 patients (184 with platinum-sensitive recurrent EOC), 92 percent of whom underwent an optimal surgical cytoreduction [
         <a href="#rid70">
          70
         </a>
         ]. HIPEC treatment resulted in a median overall survival (OS) of 49 months; for platinum-sensitive patients, it was 52 months. The median five-year OS rate for the entire cohort was 35 percent. There was a 12 percent incidence of serious (grade 3/4) complications, including leukopenia (3 percent), intra-abdominal hemorrhage (2 percent), and postoperative complications (5 percent), including one postoperative death due to an anastomotic leak resulting in peritonitis and acute renal failure.
        </p>
        <p>
         These data illustrate the risks and the potential benefits associated with HIPEC for recurrent EOC. A
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01376752&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzsJf3If9Fs1BlUGXQoEBcW26oME5SOq8HNv6%2BmsqeNdw%3D%3D&amp;TOPIC_ID=16755" target="_blank">
          randomized trial of HIPEC in recurrent EOC
         </a>
         is underway. Until more data are available, we do not administer HIPEC treatment for recurrent EOC outside of a clinical trial. The administration of HIPEC in the treatment of appendiceal carcinoma and pseudomyxoma peritonei is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2527.html" rel="external">
          "Well-differentiated neuroendocrine tumors of the appendix"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1816998100">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119533.html" rel="external">
          "Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1846265634">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/851.html" rel="external">
          "Patient education: Treatment of ovarian cancer (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1846265641">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Despite initial therapy (usually consisting of surgical cytoreduction and platinum-taxane combination therapy), the majority of women with advanced-stage ovarian cancer will relapse and require additional treatment. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The management of relapsed disease is stratified based upon the amount of time that has elapsed between the completion of platinum-based treatment and the detection of relapse, known as the platinum-free interval (PFI). The PFI correlates with progression-free survival (PFS), overall survival (OS), and response to subsequent treatment (see
         <a class="local">
          'Relevance of the platinum-free interval'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a PFI of six months or longer are considered to have platinum-sensitive disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a PFI of less than six months are considered to have platinum-resistant disease. (See
         <a class="medical medical_review" href="/z/d/html/3240.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-resistant disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with platinum-sensitive recurrent EOC have a high probability of responding again to platinum-based treatment at the time of relapse and should be offered both secondary cytoreduction and second-line systemic therapy. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For women with platinum-sensitive ovarian cancer, we recommend treatment with a platinum-based regimen rather than a nonplatinum regimen (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Given improvements in PFS and OS, we also suggest addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ), to be initiated with chemotherapy and continued as maintenance. However, some women may opt to avoid it given the potential for added toxicity. (See
         <a class="local">
          'Maintenance therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Our preferred choice of platinum regimen is
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         , although carboplatin with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         may also be used. Additionally, for those who will not be treated with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , carboplatin plus liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         is an additional alternative, with lesser degrees of neuropathy and alopecia than carboplatin and paclitaxel. We proceed with chemotherapy to best response or until unacceptable toxicity intervenes. For women who are not candidates for treatment with carboplatin-based combinations, carboplatin as a single agent or one of the agents discussed above is reasonable. (See
         <a class="local">
          'Single-agent therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women with a known breast cancer susceptibility gene (
         <em>
          BRCA
         </em>
         ) mutation, management is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/121057.html" rel="external">
          "Management of ovarian cancer associated with BRCA and other genetic mutations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women who relapse solely by cancer antigen (CA) 125 (with no evidence of disease on imaging and who are asymptomatic), we recommend surveillance (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, endocrine therapy is an appropriate alternative for those who are not comfortable with surveillance alone. We reserve chemotherapy or other treatments for women who develop signs or symptoms related to recurrent EOC, or for those with significant growth on radiographic imaging in anticipation of preventing the onset of imminent symptoms. (See
         <a class="local">
          'Recurrence based on CA 125 only'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3239.html" rel="external">
          "First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer", section on 'Post-treatment surveillance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1550808349">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert L Coleman, MD, FACOG, FACS, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pignata S, Scambia G, Bologna A, et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. J Clin Oncol 2017; 35:3347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantù MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanaboni F, Scarfone G, Presti M, et al. Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide. Gynecol Oncol 1991; 43:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrandina G, Ludovisi M, De Vincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol 2007; 18:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Burg ME, Hoff AM, van Lent M, et al. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 1991; 27:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss G, Green S, Alberts DS, et al. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. Eur J Cancer 1991; 27:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16:1494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol Oncol 2009; 115:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pignata S, Scambia G, Raspagliesi R, et al. The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. J Clin Oncol 2016; 34S: ASCO #5505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361:2099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24:4699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrie TA, Bryant A, Cameron A, et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 2013; :CD006910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfisterer J, Dean AP, Baumann K, et al. Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs.carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG). Ann Oncol 2018; 29S:vii332; ESMO #993O.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strauss HG, Henze A, Teichmann A, et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol 2007; 104:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose PG, Smrekar M, Fusco N. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol 2005; 96:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozas G, Bamias A, Koutsoukou V, et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 2007; 104:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28:3323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly F, Ray-Coquard I, Fabbro M, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011; 122:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012; 107:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson JM, Alzghari S, Ahn C, et al. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 2013; 18:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly F, Petit T, Pautier P, et al. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. Gynecol Oncol 2009; 115:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28:3107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xenidis N, Neanidis K, Amarantidis K, et al. Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer. Cancer Chemother Pharmacol 2011; 67:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrero AB, Martín-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006; 66:8155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris R, Alvarez RD, Andrews S, et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol 2008; 109:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell SK, Carson LF, Judson P, Downs LS Jr. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. Int J Gynecol Cancer 2005; 15:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001; 83:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teneriello MG, Tseng PC, Crozier M, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009; 27:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 122:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007; 97:1618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2015; 139:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30:2039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aghajanian C, Goff B, Nycum LR, et al. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecol Oncol 2014; 133:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pignata S, Lorusso D, Joly F, et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol 2018; 36S: ASCO #5506.
          </a>
         </li>
         <li class="breakAll">
          Bevacizumab for intravenous infusion. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125085s317lbl.pdf (Accessed on August 20, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pignata S, Lorusso D, Joly F, et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol 2021; 22:267.
          </a>
         </li>
         <li class="breakAll">
          Medication guide for Lynparza olaparib tablets. US Food and Drug Administration, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf (Accessed on September 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedlander M, Matulonis U, Gourley C, et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018; 119:1075.
          </a>
         </li>
         <li class="breakAll">
          Dear Health Care Provider Letter (Niraparib). GSK. December 2022. Available at: https://www.zejulahcp.com/content/dam/cf-pharma/hcp-zejulahcp-v2/en_US/pdf/Zejula-(niraparib)DearHCPLetterDec2022.pdf (Accessed on December 16, 2022).
         </li>
         <li class="breakAll">
          RUBRACA® (rucaparib) tablets, for oral use. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf (Accessed on January 04, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oza AM, Lorusso D, Aghajanian C, et al. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. J Clin Oncol 2020; 38:3494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman RL, Oza AM, Lorusso D, et al. 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Int J Gynecol Cancer 2022; 32(S2).
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dizon DS. PARP inhibitors for targeted treatment in ovarian cancer. Lancet 2017; 390:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016; 375:2154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Campo JM, Matulonis UA, Malander S, et al. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol 2019; 37:2968.
          </a>
         </li>
         <li class="breakAll">
          Dear Health Care Provider Letter (Niraparib). GSK. November 2022. Available at: https://www.zejulahcp.com/content/dam/cf-pharma/hcp-zejulahcp-v2/en_US/pdf/ZEJULA%20(niraparib)%20Dear%20HCP%20Letter%20November%202022.pdf (Accessed on December 16, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu X et. LBA29 - Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA). ESMO Virtual Congress 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22:3120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurteau JA, Brady MF, Darcy KM, et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol 2010; 119:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007; 13:3617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004; 95:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996; 26:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sales E, Penson RT, Sullivan LA, et al. A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. J Clin Oncol 2012; 30S: ASCO #5029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallion H, Christopherson WA, Coleman RL, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990; 82:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol 2012; 19:4052.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16755 Version 64.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28825853" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11870165" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1999708" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1959783" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470449" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1827305" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1827275" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9552057" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19800107" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12826431" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16966687" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23835762" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs.carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17069876" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15661211" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17052747" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20498395" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21575983" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22836511" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23881990" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19773043" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20516432" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20221602" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912194" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20643862" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9469322" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11454878" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18410954" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16174226" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11606080" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18281662" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19224848" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21497382" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15774779" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18000504" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18024863" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18165643" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26271155" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22529265" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24508841" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28438473" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33539744" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33539744" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22452356" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30353045" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30353045" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30353045" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28916367" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32840418" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28916370" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : PARP inhibitors for targeted treatment in ovarian cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27717299" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31173551" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31173551" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : LBA29 - Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284263" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20846715" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17575226" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15491759" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8531847" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502492" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25218906" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20921468" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16445633" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2313735" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22825772" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
